Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimizing Ocular Outcomes: A Dual-armed Study for Periorbital Burn Management
NCT06362226Phase 1Withdrawn
- Sponsor
- Virginia Commonwealth University
- Start
- Jun 2026
- Primary completion
- Jun 2026
- Modality
- Orthosteric Ligands
01
Overview
Phase 1 trial of fluorouracil and triamcinolone in periorbital burn (2 arms), sponsored by Virginia Commonwealth University. Primary endpoints: Comparison of wound healing time at 12 months, Comparison of infection rate at 12 months and 1 more. Planned start Jun 2026; status: withdrawn.
02
Drugs
fluorouraciltriamcinolone
03
Conditions
periorbital burn
Beyond the preview
Go deeper on NCT06362226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06362226.